Alnylam Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript
Good morning. Before I get going, let me just read our disclosures. Please note that all-important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, are up here at the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk.
Once again, thank you for attending. I'm David Lebowitz, one of the biotechnology analysts here. And on stage with me, I have from Alnylam Pharmaceuticals, CEO, John Maraganore; and the Head of Business Development or Head of Business, Andy Orth. Thank you so much for being here. I guess, just quickly, give a little bit top level on Alnylam and your mission.
Sure. Thanks, Dave. Pleasure to be here. Alnylam is now a global commercial company that is developing, commercializing RNAi therapeutics around the world. Our advanced
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
